Literature DB >> 8570029

Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study.

V Hadrava1, P Blier, T Dennis, C Ortemann, C de Montigny.   

Abstract

Flesinoxan is a high affinity and selective 5-hydroxytryptamine1A (5-HT1A) ligand which, unlike the 5-HT1A agonists of the azapirone class, does not generate 1-(2-pyrimidinyl)piperazine, an alpha 2-adrenoreceptor antagonist. In view of potential antidepressant effects of flesinoxan, this study was undertaken to characterize its 5-HT1A properties in the rat brain using in vivo electrophysiology and hypothermia paradigms. The suppressant effect of microiontophoretic applications of flesinoxan on the firing activity of CA3 pyramidal neurons was blocked by concomitant application of the 5-HT1A antagonist BMY 7378. Compared to gepirone, the efficacy of flesinoxan to suppress the firing activity of CA3 pyramidal neurons was significantly greater. While the coapplication of flesinoxan antagonized the suppressant effect of 5-HT on CA3 pyramidal neurons, it failed to do so on dorsal raphe 5-HT neurons, indicating that flesinoxan acts as a partial agonist at postsynaptic and as a full agonist at presynaptic 5-HT1A receptors. The capacity of flesinoxan to antagonize the effect of 5-HT on CA3 pyramidal neurons was similar to that of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and significantly greater than that of gepirone. The intravenous administration of flesinoxan suppressed the firing activity of both CA3 pyramidal neurons and dorsal raphe 5-HT neurons. However, when compared to 8-OH-DPAT, significantly higher doses of flesinoxan were required. The acute brain penetration of [3H]flesinoxan and [3H]8-OH-DPAT was, therefore, determined. Nine minutes after intravenous administration, [3H]8-OH-DPAT reached significantly greater brain concentration than [3H]flesinoxan. Subcutaneous administration of flesinoxan and 8-OH-DPAT produced a dose-dependent hypothermia. The flesinoxan-induced hypothermia was significantly attenuated by prior administration of the non-selective 5-HT1A antagonist pindolol and the 5-HT1/2 antagonist methysergide. Similar degrees of hypothermia were achieved with 3 mg/kg of flesinoxan and 0.5 mg/kg of 8-OH-DPAT. The maximal effect of flesinoxan occurred 30 min later than that of 8-OH-DPAT and faded more slowly. The 5-HT1A properties of flesinoxan suggest that it may be an effective anxiolytic/antidepressant agent.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570029     DOI: 10.1016/0028-3908(95)00098-q

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

Review 1.  Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

Authors:  Yukihiro Ohno
Journal:  CNS Neurosci Ther       Date:  2010-11-21       Impact factor: 5.243

2.  Discovery of Natural Product-Derived 5-HT1A Receptor Binders by Cheminfomatics Modeling of Known Binders, High Throughput Screening and Experimental Validation.

Authors:  Man Luo; Terry-Elinor Reid; Xiang Simon Wang
Journal:  Comb Chem High Throughput Screen       Date:  2015       Impact factor: 1.339

3.  Contractile effects of 5-hydroxytryptamine and 5-carboxamidotryptamine in the equine jejunum.

Authors:  Cathérine Delesalle; Piet Deprez; Jan A J Schuurkes; Romain A Lefebvre
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

4.  Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.

Authors:  Khanh Q Nguyen; Yoshihiro Tohyama; Arata Watanabe; Shu Hasegawa; Ivan Skelin; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-27       Impact factor: 3.921

5.  In vivo characterization of 5-HT1A receptor-mediated gastric relaxation in conscious dogs.

Authors:  P Janssen; N H Prins; B Moreaux; A L Meulemans; R A Lefebvre
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

6.  Agonist-induced internalization of serotonin-1a receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors).

Authors:  M Riad; K C Watkins; E Doucet; M Hamon; L Descarries
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

7.  Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors.

Authors:  Saki Shimizu; Yukihiro Ohno
Journal:  Aging Dis       Date:  2012-11-29       Impact factor: 6.745

Review 8.  In vivo electrophysiological recordings of the effects of antidepressant drugs.

Authors:  Paul J Fitzgerald; Brendon O Watson
Journal:  Exp Brain Res       Date:  2019-05-11       Impact factor: 1.972

9.  Activation of somatodendritic 5-HT1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test.

Authors:  Yulong Zhao; Elisabeth Y Bijlsma; Freija Ter Heegde; Monika P Verdouw; J Garssen; Adrian Newman-Tancredi; Lucianne Groenink
Journal:  Psychopharmacology (Berl)       Date:  2018-12-12       Impact factor: 4.530

Review 10.  The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory.

Authors:  Oliver Stiedl; Elpiniki Pappa; Åsa Konradsson-Geuken; Sven Ove Ögren
Journal:  Front Pharmacol       Date:  2015-08-07       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.